These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21622715)

  • 1. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Park MA; Yacoub A; Hamed HA; Tang Y; Cruickshanks N; Eulitt P; Hubbard N; Tye G; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Cancer Res; 2011 Jul; 71(14):4955-67. PubMed ID: 21622715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Hamed HA; Tang Y; Cruickshanks N; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Autophagy; 2011 Oct; 7(10):1261-2. PubMed ID: 21814046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
    Bareford MD; Hamed HA; Allegood J; Cruickshanks N; Poklepovic A; Park MA; Ogretmen B; Spiegel S; Grant S; Dent P
    Cancer Biol Ther; 2012 Jul; 13(9):793-803. PubMed ID: 22673740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
    Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
    Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
    Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
    Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
    Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
    Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
    Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
    Booth L; Roberts JL; Poklepovic A; Dent P
    Oncotarget; 2017 Feb; 8(8):13464-13475. PubMed ID: 28088782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
    J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.